GlassScriptPhysician profile
Rachel E Rosen
NPI 1568437929
$6,572.89
in general payments reported to CMS, 2019-2025
39 companies · $691 in 2025
The $691 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $895 · 2021: $1,132 · 2022: $1,105 · 2023: $1,030 · 2024: $1,044 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,863.62 | 2019-2025 | Ubrelvy, Vraylar, Viberzi |
| Novo Nordisk INC | $645.45 | 2019-2025 | Wegovy |
| Pfizer INC. | $475.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $462.87 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Allergan, INC. | $434.30 | 2019-2020 | |
| Lilly USA, LLC | $283.32 | 2019-2025 | Mounjaro, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.70 | 2019-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $216.56 | 2021-2025 | Rexulti |
| Astellas Pharma US INC | $198.38 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $158.88 | 2022 | |
| Axsome Therapeutics, INC. | $154.97 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $139.97 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $110.44 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $97.96 | 2019-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.